Anixa Biosciences' breast cancer vaccine elicited targeted immune responses in 70% of patients. Click here to read an ...

After 12 weeks of treatment, 75% of per-protocol patients receiving 0.05% urcosimod showed greater than 80% reduction in neuropathic corneal pain (NCP), as measured by Visual Analogue Scale (VAS), dem ...